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Am J Med Genet Part A 9999:1–8.Previous studies have shown that over 40% of babies with Down
syndrome have a major cardiac anomaly and are more likely to
have other major congenital anomalies. Since 2000, many coun-
tries in Europe have introduced national antenatal screening
programs for Down syndrome. This study aimed to determine if
the introductionof these screeningprograms and the subsequent
termination of prenatally detected pregnancies were associated
with any decline in the prevalence of additional anomalies in
babies bornwithDown syndrome.The study sample consisted of
7,044 live births and fetal deathswithDown syndrome registered
in 28 European population-based congenital anomaly registries
covering seven million births during 2000–2010. Overall, 43.6%
(95% CI: 42.4–44.7%) of births with Down syndrome had a
cardiac anomaly and 15.0% (14.2–15.8%) had a non-cardiac
anomaly. Female babies withDown syndromewere significantly
more likely to have a cardiac anomaly compared to male babies
(47.6% compared with 40.4%, P< 0.001) and significantly less
likely to have a non-cardiac anomaly (12.9% compared with
16.7%, P< 0.001). The prevalence of cardiac and non-cardiac
congenital anomalies in babies with Down syndrome has
remained constant, suggesting that population screening for
Down syndrome and subsequent terminations has not influ-
enced the prevalence of specific congenital anomalies in these
babies.  2014 Wiley Periodicals, Inc.
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diagnosisINTRODUCTION
Population-based studies based on data from 1976 to 2004 have
shown that over 40% of babies with Down syndrome have a major
cardiac anomaly, the most common being atrioventricular septal
defects (AVSD) [Kallen et al., 1996; Freeman et al., 1998, 2008; Stoll
et al., 1998; Torfs and Christianson, 1998; Bell et al., 2003; Rankin
et al., 2012]. Other major congenital anomalies, particularly diges-
tive system anomalies, were also more frequent than in babies
without Down syndrome [Kallen et al., 1996; Bell et al., 2003;
Freeman et al., 2009; Rankin et al., 2012]. In 1999 measuring the
nuchal translucency (NT) of the fetus with ultrasound, in combi-
nation with several serum markers, was found to be an adequate
method of screening for Down syndrome in the first trimester of
pregnancy [Spencer et al., 1999; Wald et al., 2003]. Measuring the
NT of the fetus is also considered as a potential antenatal screening
test for cardiac anomalies [Hyett et al., 1999; Bruns et al., 2006;
Mu¨ller et al., 2007; Mogra et al., 2011]. Many cardiac and other
congenital anomalies are detectable during fetal anomaly ultra-
sound scans performed at 18–22 weeks gestation. Hence it might
be expected that fetuses with Down syndrome and cardiac orother structural congenital anomalies may be more likely to be
detected than those without. By 2010, 12 of 14 countries providing
data to EUROCAT (a European network of population-based
registries for the epidemiologic surveillance of congenital anoma-
lies) had widespread availability of antenatal screening for
Down syndrome including NT measurements and ultrasound
scans performed at 18–22 weeks [EUROCAT, 2005a, 2010; Boyd
et al., 2008]. As the presence of major congenital anomalies has
implications for subsequentmorbidity andmortality andprovision
of services, it is important to know the prevalence of cardiac
and other congenital anomalies in babies with Down syndrome
[Rankin et al., 2012].
This study aimed to quantify the prevalence of cardiac and other
anomalies in babies born with Down syndrome from 2000 to 2010
and to determine if the widespread availability of antenatal screen-
ing for Down syndrome was associated with any decline in the
prevalence of specific anomalies in these babies over this time
period.METHODS
Data for this study were extracted from the European Surveillance
of Congenital Anomalies (EUROCAT) Central Register. In
2011 EUROCAT had 41 population based member registries
in 20 countries covering 31% of all births in Europe [Boyd
et al., 2011]. Information on member registries and their methods
of case ascertainment are available [Greenlees et al., 2011].
Each registry sends an anonymized uniformly coded dataset
to EUROCAT Central Registry containing information on cases
of major congenital anomaly registered in the local population.
Cases include live births, fetal deaths at or after 20 weeks of
gestation, and terminations of pregnancy for fetal anomaly
MORRIS ET AL. 3(TOPFA) at any gestation. Up to nine anomalies for each case are
coded according to the International Classification of Diseases
with British Paediatric Association extension code (ICD9/BPA
or ICD10/BPA).
In aprevious EUROCATstudy, cardiac anomalieswere classified
into three subgroups [Dolk et al., 2011], based on the perinatal
mortality rate for each of these subgroups among non-chromo-
somal cases from I (high perinatal mortality) to III (low perinatal
mortality): (see Box 1). Six percent of all cardiac anomalieswere not
classified to a severity group because the ICD code was for a poorly
specified cardiac anomaly of unknown severity. These cases were
included in counts relating to all cardiac anomalies but not in a
severity category.SEVERITY OF CARDIAC ANOMALIES
Severity I (SI): single ventricle, hypoplastic left heart, hypoplastic
right heart, Ebstein anomaly, and tricuspid atresia (univentric-
ular cardiac anomalies).
Severity II (SII): pulmonary valve atresia, common arterial
truncus, AVSD, aortic valve atresia/stenosis, transposition of
great vessels, tetralogy of Fallot, total anomalous pulmonary
venous return, and coarctation of aorta, without additional
cardiac anomalies classified as SI.
Severity III (SIII): ventricular septal defect (VSD), atrial septal
defect (ASD), pulmonary valve stenosis, without additional
cardiac anomalies classified as SI or SII. Isolated Patent ductus
arteriosus (PDA) in term infants.All anomalies were coded using the EUROCAT guide 1.3
[EUROCAT, 2005b]
For this study, the criteria for including registries were that:
maternal age was recorded for 80% of all births in the registry
population; and 75% ascertainment of Down syndrome accord-
ing to an adapted version of the Down Syndrome Data Quality
Indicator (DQI) [Loane et al., 2011] for 2005–2009. This Down
syndrome DQI calculates the ratio of the number of observed to
numberof expected cases ofDown syndrome for each registry based
on thematernal age profile, external standardmaternal age-specific
rates and fetal survival correction factors to 20 weeks of gestation
(see appendix Loane et al., 2013). The final study population
consisted of 27 registries in 18 countries covering seven million
births during 2000–2010. Cases of Down syndrome (ICD10 codes:
Q90, ICD9 code: 7580) were extracted from the central database in
June 2012.The study yearswere chosenbecause from2000 standard
prenatal care in many European countries included having a fetal
echogramand therefore cardiac anomalieswere likely tobedetected
antenatally [EUROCAT, 2005a; Boyd et al., 2008]. This study did
not distinguish between Down syndrome arising as a trisomy,
translocation or mosaic. Although most of the registries indicated
that they consult or receive direct notification of all Down syn-
drome cases from cytogenetic laboratories in their region, some
registries identified potential problems beyond their control; hencesome cases may be missed. Saxony-Anhalt (Germany) and East
Midlands & South Yorkshire (UK) have notifications from some
but not all of the cytogenetic labs in their region. Wielkopolska
(Poland) has complete information on live birth cases, but TOPFA
cases are missed as the registry does not register TOPFAs; however,
these are likely to be few as TOPFA is only allowed in Poland for
“severe, irreversible damage of the fetus.” Norway receives cases
through themedical birth notification form fromdelivery units and
neonatal intensive care units and misses about 20% of Down
syndrome cases [EUROCAT, 2010]. In Cork and Kerry (Ireland)
and South East Ireland case finding was mainly via obstetric or
pediatric records. Four registries do not provide any information
on whether a postmortem examination was performed or not and
several other registries have a high proportion of missing informa-
tion on whether a postmortem examination was performed or not.
The proportion of TOPFA with gestations of at least 15 weeks that
had a postmortem reported varies considerably from 79% in South
Portugal down to only 12% in East Midlands and South Yorkshire.STATISTICAL METHODS
Trends in the prevalence of cardiac anomalies and non-cardiac
congenital anomalies were analyzed using multilevel logistic mod-
els to take account of differences among the registers. Ninety five
percent confidence intervals for proportions were calculated using
the binomial distribution. Sensitivity analyses were performed
excludingMalta and Ireland (whereTOPFA isnot legal) andPoland
(where TOPFA is only available for “severe, irreversible damage of
the fetus”) to ensure that these three countries were not influencing
the overall results. Statistical analyseswere performed using STATA
version 10 (Statacorp LP, College Station, TX).RESULTS
There were 14,109 cases with Down syndrome of whom 6,738 were
live births, 306 fetal deaths, and 7,065 TOPFAs. Table I shows the
proportionsof births (live births and fetal deaths) andTOPFAswith
Downsyndromewith a cardiac anomaly diagnosed according to the
severity of the anomaly. Table I also shows the proportion of
TOPFAs that had a postmortem examination reported. Overall,
43.6% (42.4–44.7%) of births with Down syndrome had a cardiac
anomaly,while only 8.1%(7.7.4–8.7%)ofTOPFAshadadiagnosed
cardiac anomaly. This increased to 18.1% (16.0–20.4%) when only
those TOPFAs with a postmortem examination reported were
included. As expected the more severe the diagnosis, the more
likely that it was recorded for the TOPFAs. The proportion with a
cardiac anomaly with high perinatal mortality was similar in both
births and TOPFAs with a postmortem examination reported
(0.3% (0.2–0.5%) and 0.5% (0.2–1.1%), respectively).
Table I shows a similar pattern with non-cardiac congenital
anomalies. Overall, 15.0% (14.2–15.8%) of births with Down
syndrome had a non-cardiac congenital anomaly, while only
7.3% (6.7–7.9%) of TOPFAs had a diagnosed non-cardiac congen-
ital anomaly.However, this increased to 16.8% (14.8–19.1%)when
only those TOPFAs with a postmortem examination reported were
included, which was significantly higher than in live births and fetal
deaths. The most common non-cardiac congenital anomalies
TABLE I. Associated Congenital Anomalies Present in Cases With Down Syndrome
Type of congenital anomaly
Live births and fetal deaths
from 20 weeks of gestation
with Down syndrome (n¼ 7,044)
TOPFAsa with Down
syndrome (n¼ 7,065)
TOPFAsa with Down syndrome
who have had a Postmortem
examination (n¼ 1,217)
Number
Proportion of births (%)
(95% CI) Number
Proportion of TOPFAs (%)
(95% CI) Number
Proportion of TOPFAs (%)
(95% CI)
Any cardiac anomalyb 3,068 43.6 (42.4–44.7) 570 8.1 (7.4–8.7) 220 18.1 (16.0–20.4)
Severity of cardiac anomaly
High perinatal mortalityc 21 0.3 (0.2–0.5) 14 0.2 (0.1–0.3) 6 0.5 (0.2–1.1)
Medium perinatal mortalityc 1,111 15.8 (14.9–16.6) 332 4.7 (4.2–5.2) 115 9.4 (7.9–11.2)
Low perinatal mortalityc 1,661 23.6 (22.6–24.6) 153 2.42 (1.8–2.5) 84 6.9 (5.5–8.5)
Any non-cardiac anomalyb 1,056 15.0 (14.2–15.8) 517 7.3 (6.7–7.9) 205 16.8 (14.8–19.1)
No associated anomaly 3,503 49.7 (48.6–50.9) 6,113 86.5 (85.7–87.3) 875 71.9 (69.3–74.4)
aTOPFA: termination of pregnancy for fetal anomaly.
bCases with both a cardiac anomaly and a non-cardiac anomaly will be present in both rows of the table.
cHigh perinatal mortality includes single ventricle, hypoplastic left heart, hypoplastic right heart, Ebstein anomaly, and tricuspid atresia (univentricular cardiac anomalies). Medium perinatal mortality
includes pulmonary valve atresia, common arterial truncus, atrioventricular septal defects, aortic valve atresia/stenosis, transposition of great vessels, tetralogy of Fallot, total anomalous pulmonary
venous return, and coarctation of aorta,without additional cardiac anomalies classifiedas high perinatalmortality. Lowperinatalmortality includes ventricular septal defect, atrial septal defect, pulmonary
valve stenosis, without additional cardiac anomalies classified as medium or high perinatal mortality. Isolated Patent ductus arteriosus in term infants.
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART Arecorded in cases with postmortem examinations included limb
anomalies and digestive system anomalies (both over 5%).
Table I demonstrates that there was under-reporting of medium
and low mortality cardiac anomalies in TOPFAs, even when a
postmortem examination had been performed. When examined
according to gestation, TOPFAs occurring at earlier gestations
(particularly before 20weeks) had significantly fewer cardiac anom-
alies reported. Figure 1 shows that the proportion of all cases with
Down syndrome that were TOPFAs occurring prior to 15 weeks
gestation increased significantly since 2000 from6% to25% in 2010,
with themedian gestational age decreasing from18 to 15weeks. The
proportion of all Down syndrome cases that were TOPFAs occur-
ring after 15 weeks gestation decreased from 41% down to 36%.FIG. 1. Terminations of pregnancy for a fetal anomaly as a
proportion of all diagnoses of Down syndrome (live births, fetal
deaths from 20 weeks of gestation, and TOPFA at any gestation)
according to gestation, 2000–2010.Trends over time were examined using multi-level models to
allow for differences between registers. There was no evidence of
a trend in the proportions of births with Down syndrome with
any associated cardiac anomaly, severe cardiac anomaly (severity 1
and 2) or non-cardiac congenital anomaly since 2000. This is
illustrated in Figure 2, which shows the unadjusted proportions
of births with Down syndrome with any associated cardiacFIG. 2. The proportion of live births and fetal deaths from
20 weeks of gestation with Down syndrome with associated
congenital anomalies according to severity of the cardiac
anomaly† and year of birth, 2000–2010. †Severe cardiac
anomalies include single ventricle, hypoplastic left heart,
hypoplastic right heart, Ebstein anomaly, tricuspid atresia,
pulmonary valve atresia, common arterial truncus, atrioventricu-
lar septal defects, aortic valve atresia/stenosis, transposition of
great vessels, tetralogy of Fallot, total anomalous pulmonary
venous return, and coarctation of aorta.
TABLE II. Associated Congenital Anomalies Present in Live Births and Fetal Deaths from 20 Weeks of Gestation With Down Syndrome
According to Sex, 2000–2010
Type of congenital anomalya
Males with Down
syndrome (n¼ 3,905)
Females with Down
syndrome (n¼ 3,120)
Odds male versus female
(95% CI)Number
Proportion of births (%)
(95% CI) Number
Proportion of births (%)
(95% CI)
Nervous system 38 0.97 (0.69–1.33) 27 0.87 (0.57–1.26) 1.13 (0.69–1.84)
Neural tube defects 3 0.08 (0.02–0.22) 0 0 (0–0.12) —
Hydrocephalus 11 0.28 (0.14–0.50) 9 0.29 (0.13–0.55) 0.98 (0.41–2.3)
Microcephaly 11 0.28 (0.14–0.50) 3 0.10 (0.02–0.28) 2.94 (0.88–9.78)
Eye 63 1.61 (1.24–2.06) 52 1.67 (1.25–2.18) 0.97 (0.67–1.4)
Anophthalmos/micropthalmos 3 0.08 (0.02–0.22) 0 0 (0–0.12) —
Congenital cataract 11 0.28 (0.14–0.50) 17 0.54 (0.32–0.87) 0.52 (0.25–1.08)
Congenital glaucoma 1 0.03 (0.01–0.14) 2 0.06 (0.01–0.23) 0.40 (0.01–3.05)
Ear, face, and neck 45 1.15 (0.84–1.54) 36 1.15 (0.81–1.59) 1.00 (0.64–1.55)
Cardiac anomalies 1,579 40.40 (38.9–42.0) 1,485 47.60 (45.83–49.37) 0.75 (0.68–0.82)b
Severe cardiac anomalies 557 14.26 (13.2–15.4) 574 18.40 (17.05–19.8) 0.74 (0.65–0.84)b
Common arterial truncus 5 0.13 (0.04–0.30) 1 0.03 (0–0.18) 4.00 (0.55–29.1)
Transposition of great arteries 5 0.13 (0.04–0.30) 4 0.13 (0.03–0.33) 1.00 (0.29–3.44)
Single ventricle 1 0.03 (0.00–0.14) 2 0.06 (0.01–0.23) 0.40 (0.01–3.05)
Ventricular septal defect 518 13.27 (12.2–14.4) 500 16.03 (14.75–17.36) 0.80 (0.70–0.92)b
Atrial septal defect 665 17.03 (15.9–18.2) 580 18.59 (17.24–20.0) 0.90 (0.79–1.02)
Atrioventricular septal defect 471 12.06 (11.1–13.1) 506 16.22 (14.94–17.56) 0.71 (0.62–0.81)
Tetralogy of fallot 68 1.74 (1.35–2.20) 47 1.51 (1.11–2.00) 1.16 (0.80–1.68)
Tricuspid atresia and stenosis 5 0.13 (0.04–0.30) 4 0.13 (0.03–0.33) 1.00 (0.29–3.44)
Ebstein anomaly 5 0.13 (0.04–0.30) 3 0.10 (0.02–0.28) 1.33 (0.35–5.04)
Pulmonary valve stenosis 20 0.51 (0.31–0.79) 22 0.71 (0.44–1.07) 0.72 (0.40–1.32)
Pulmonary valve atresia 5 0.13 (0.04–0.30) 3 0.10 (0.02–0.28) 1.33 (0.35–5.04)
Aortic valve atresia/stenosis 2 0.05 (0.01–0.18) 1 0.03 (0.00–0.18) 1.60 (0.15–17.3)
Hypoplastic right heart 0 0 (0.00–0.09) 3 0.10 (0.02–0.28) 0.00 (0.00–1.02)
Coarctation of aorta 35 0.9 (0.63–1.24) 33 1.06 (0.73–1.48) 0.85 (0.53–1.36)
Patent ductus arteriosus as only
cardiac anomaly in term infants
(>¼37 weeks)
74 1.90 (1.49–2.37) 63 2.02 (1.56–2.58) 0.94 (0.67–1.31)
Respiratory 47 1.20 (0.89–1.60) 39 1.25 (0.89–1.70) 0.96 (0.63–1.47)
Choanal atresia 7 0.18 (0.07–0.37) 8 0.26 (0.11–0.50) 0.70 (0.26–1.85)
Oro facial clefts 19 0.49 (0.29–0.76) 12 0.38 (0.20–0.67) 1.27 (0.62–2.57)
Cleft lip with or without palate 9 0.23 (0.11–0.44) 4 0.13 (0.03–0.33) 1.80 (0.59–5.51)
Cleft palate 10 0.26 (0.12–0.47) 8 0.26 (0.11–0.50) 1.00 (0.41–2.46)
Digestive system 302 7.73 (6.91–8.62) 187 5.99 (5.19–6.88) 1.31 (1.09–1.59)b
Esophageal atresia with or without
tracheo-esophageal fistula
17 0.44 (0.25–0.70) 14 0.45 (0.25–0.75) 0.97 (0.48–1.94)
Duodenal atresia or stenosis 117 3.00 (2.48–3.58) 90 2.88 (2.33–3.53) 1.04 (0.79–1.37)
Atresia or stenosis of other parts of
small intestine
6 0.15 (0.06–0.33) 0 0 (0.00–0.12) —
Ano rectal atresia and stenosis 34 0.87 (0.60–1.21) 21 0.67 (0.42–1.03) 1.30 (0.76–2.22)
Hirschsprung disease 57 1.46 (1.11–1.89) 10 0.32 (0.15–0.59) 4.61 (2.38–8.93)b
Annular pancreas 17 0.44 (0.25–0.70) 10 0.32 (0.15–0.59) 1.36 (0.63–2.92)
Diaphragmatic hernia 9 0.23 (0.11–0.44) 6 0.19 (0.07–0.42) 1.20 (0.44–3.24)
Abdominal wall defects 14 0.36 (0.20–0.60) 4 0.13 (0.03–0.33) 2.80 (0.97–8.11)
Omphalocele 10 0.26 (0.12–0.47) 2 0.06 (0.01–0.23) 4.00 (1.00–16.3)b
Urinary 90 2.30 (1.86–2.83) 45 1.44 (1.05–1.93) 1.61 (1.13–2.31)b
Bilateral renal agenesis including
Potter syndrome
2 0.05 (0.01–0.18) 2 0.06 (0.01–0.23) 0.80 (0.14–4.52)
Renal dysplasia 10 0.26 (0.12–0.47) 1 0.03 (0.00–0.18) 8.00 (1.42–45.1)b
Congenital hydronephrosis 45 1.15 (0.84–1.54) 21 0.67 (0.42–1.03) 1.72 (1.03–2.88)b
Bladder exstrophy and/or epispadia 2 0.05 (0.01–0.18) 1 0.03 (0.00–0.18) 1.60 (0.15–17.3)
Posterior urethral valve and/or prune belly 4 0.10 (0.03–0.26) 0 0 (0.00–0.12) —
(Continued)
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TABLE II. (Continued)
Type of congenital anomalya
Males with Down
syndrome (n¼ 3,905)
Females with Down
syndrome (n¼ 3,120)
Odds male versus female
(95% CI)Number
Proportion of births (%)
(95% CI) Number
Proportion of births (%)
(95% CI)
Genital 30 0.77 (0.52–1.09) 6 0.19 (0.07–0.42) 4.02 (1.71–9.42)b
Hypospadias 24 0.61 (0.39–0.91) 0 0.00 (0.00–0.12) —
Limb 147 3.76 (3.19–4.41) 81 2.60 (2.07–3.22) 1.47 (1.12–1.93)b
Limb reduction 9 0.23 (0.11–0.44) 13 0.42 (0.22–0.71) 0.55 (0.24–1.26)
Upper limb reduction 7 0.18 (0.07–0.37) 9 0.29 (0.13–0.55) 0.62 (0.24–1.61)
Lower limb reduction 1 0.03 (0.00–0.14) 5 0.16 (0.05–0.37) 0.16 (0.01–1.03)
Talipesequinovarus 31 0.79 (0.54–1.12) 11 0.35 (0.18–0.63) 2.26 (1.15–4.45)b
Polydactyly 18 0.46 (0.27–0.73) 5 0.16 (0.05–0.37) 2.89 (1.11–7.50)b
Syndactyly 40 1.02 (0.73–1.39) 10 0.32 (0.15–0.59) 3.22 (1.63–6.36)b
Craniosynostosis 22 0.56 (0.35–0.85) 16 0.51 (0.29–0.83) 1.10 (0.58–2.07)
Congenital skin disorders 31 0.79 (0.54–1.12) 17 0.54 (0.32–0.87) 1.46 (0.81–2.62)
aAnomalies with less than three cases are excluded from the table.
bP< 0.05 difference between male and female
6 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aanomaly, severe cardiac anomaly (severity 1 and 2) or non-cardiac
congenital anomaly. The same lack of trend was evident when
Malta, Ireland and Poland were excluded from the analysis. There
was no observed change in prevalence of ASD and VSD among
births with Down syndrome over the 10 years. However, before
2005 the EUROCAT definition of ASD included a minor form
whereas after 2005 these cases were excluded. Therefore there may
have been a slight increase in ASD that was not detected due to the
coding change.
Table II demonstrates the high prevalence of other major con-
genital anomalies in babies with Down syndrome and also high-
lights the prevalence differences according to sex. The most
common cardiac anomalies were ASD, VSD, AVSD, patent ductus
arteriosus, and tetralogy of Fallot with one of these present in over
99% of births with cardiac anomalies. Female babies with Down
syndrome were significantly more likely to have a cardiac anomaly
compared with male babies (47.6% compared with 40.4%,
P< 0.001) and significantly less likely to have a non-cardiac anom-
aly (12.9% compared with 16.7%, P< 0.001). Digestive system
anomalies weremore common inmales than females. In particular,
Hirschsprung disease was almost five timesmore common inmales
than females (OR¼ 4.61; 95%CI: 2.38–8.93) and atresia or stenosis
of parts of the small intestine excluding the duodenum occurred in
sixmales and no females (P< 0.029).Urinary anomalies weremore
common inmaleswith inparticular renal dysplasia beingnine times
more likely in males than females (OR¼ 8.00; 95% CI: 1.42–45.1).
Limb anomalies were more common inmales, in particular talipes,
polydactyly, and syndactyly.DISCUSSION
The prevalence of all cardiac anomalies, severe cardiac anomalies
and non-cardiac congenital anomalies has remained constant in
babies born with Down syndrome from 2000 to 2010. Also the
observed prevalence of ASD and VSD remained constant over thestudy period, indicating that the constant prevalence of cardiac
anomalies was not due to increases in less severe cardiac anomalies
offsetting decreases in more severe cardiac anomalies.
The recorded prevalence of all associated congenital anomalies is
lower in pregnancies with Down syndrome that resulted in a
TOPFA and significantly lower in TOPFAs occurring prior to
15 weeks gestation compared with later TOPFAs (data not shown).
One explanation is that many congenital anomalies can be diag-
nosed during the routine fetal anomaly ultrasound scan, which
generally occurs at around18–22weeks gestation rather than earlier
in gestation. If first trimester screening is done, followed quickly by
adiagnostic test andsubsequentTOPFAoccurringprior to15weeks
gestation, it is unlikely that these congenital anomalies will have
been diagnosed and also less likely that a postmortem examination
will be carried out. The proportion of TOPFAs occurring prior to
15 weeks gestation has increased continually from 2000 (see Fig. 2),
reflecting the increased use of first trimester screening tests in
Europe. For women who have received a fetal anomaly ultrasound
scan before they have a TOPFA, the more severe forms of cardiac
and non-cardiac congenital anomalies are searched for and
reported, while the less severe congenital anomalies are not detect-
able by ultrasound and are only investigated after the birth of the
infant with Down syndrome.
The most common screening tests for Down syndrome in the
first trimester involvemeasuring theNTof the fetus between 11 and
13 weeks gestation. A large NT value has also been shown to be
predictiveof a cardiac anomaly [Hyett et al., 1999; Bruns et al., 2006;
Mu¨ller et al., 2007]. Fetuses detected through this screeningmethod
might be expected to have a higher prevalence of cardiac anomalies
than other fetuses with Down syndrome. However, Mogra et al.
[2011] reported that among fetuses with Down syndrome, the
presence of structural cardiac anomalies was not associated with an
increased NT. Also the detection rates of screening tests including
an NTmeasurement are over 85% for the commonly used 3% false
positive rate [Spencer et al., 1999; Wald et al., 2003] and therefore
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not just the 44% with a cardiac anomaly. This confirms our
results that increases in prenatal detection have not altered the
prevalence of associated congenital anomalies in births with Down
syndrome.
Population screening in Europe has not reduced the live birth
prevalenceofDown syndrome [Loane et al., 2013] and therefore the
contributionofDown syndromewith cardiac anomalies to the total
pediatric cardiac anomaly caseload will have remained constant in
Europe. Dolk et al. [2011] estimated this contribution to vary from
3% to 4% (Italy, France, and Switzerland) to 15–19% (Ireland and
Malta) from 2000 to 2005, consistent with the 6.4% reported by
Dadvand et al. [2008] in Northern England.
The birth prevalence of specific cardiac anomalies among babies
with Down syndrome in this study is in agreement with the
prevalence observed in other studies [Kallen et al., 1996; Freeman
et al., 1998, 2008; Stoll et al., 1998;Torfs andChristianson, 1998;Bell
et al., 2003;Mogra et al., 2011; Rankin et al., 2012]. In particular, the
proportion of cardiac anomalies that are severe was similar to that
observed by Kallen et al. [1996] in data from 1976 to 1991.
In a meta-analysis from the results of five population-based
studies of all births (not just those with Down syndrome).
Tennant et al. [2011] showed that VSDs, ASDs, and AVSDs were
more common in females and the other cardiac anomalies were
more common in males. Our findings in births with Down
syndrome are consistent with these results. Due to the large
proportion of VSDs, ASDs, and AVSDs, overall cardiac anomalies
are more common in females than males with Down syndrome in
this study, as has been observed in other studies [Kallen et al., 1996;
Freeman et al., 1998]. Similarly the observations in this study that
digestive system anomalies (particularly Hirschsprung disease and
atresia or stenosis of parts of the small intestine excluding the
duodenum), urinary anomalies (in particular renal dysplasias)
and limb anomalies were all more common in males has been
reported in other studies for live births with Down syndrome
[Badner et al., 1990; Kallen et al., 1996; Freeman et al., 2009; Ieiri
et al., 2009] and for all live births [Tennant et al., 2011]. Potential
mechanisms for these sex-specific differences have been proposed
[Lary and Paulozzi, 2001].
The strengths of this study are that it uses recent population-
based data across Europe covering a time period with a generally
high prenatal detection rate and a high number of TOPFAs in
countries where TOPFA is legal. All themembers of EUROCATuse
similar inclusion criteria and have a consistent approach to data
collection, coding, and recording.
The weaknesses of this study are that for babies with a cardiac
anomaly and a prenatal diagnosis, we do not know if the prenatal
diagnosis refers to Down syndrome or to the cardiac anomaly. The
information on which anomalies were diagnosed prenatally and
which were only diagnosed after birth will not be available until
2015. In addition, many registries provided EUROCAT central
registry with incomplete information on whether a postmortem
examinationhadbeenperformedornot.Thismeans that therewere
more TOPFAs with postmortem examinations than reported in
Table I. However, the prevalence of the anomalies in the TOPFAs
with postmortem examinations in Table I is unlikely to be a biased
sample of all TOPFAs with postmortem examinations. A furtherweakness is that not all registers send the precise karyotype to
central registry and therefore this study could not distinguish
between Down syndrome arising as a trisomy, translocation, or
mosaic.
The birth prevalence of associated cardiac anomalies and non-
cardiac congenital anomalies among babies with Down syndrome
remained unchanged from 2000 to 2010 and was similar to that
observed in much earlier studies before the occurrence of high
levels of TOPFA. Although both first trimester screening tests and
second trimester fetal anomaly ultrasound scans are likely to detect
cardiac and other congenital anomalies, this has not altered
the prevalence of associated congenital anomalies in births with
Down syndrome.REFERENCES
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